TRANSITION AGREEMENTTransition Agreement • May 22nd, 2013 • Cardiome Pharma Corp • Pharmaceutical preparations
Contract Type FiledMay 22nd, 2013 Company IndustryThis Transition Agreement (the “Agreement”) is made and entered into as of April 25, 2013 (the “Effective Date”) by and between CARDIOME PHARMA CORP., a Canadian corporation with offices at 6190 Agronomy Rd., Suite 405, Vancouver, B.C., Canada, V6T 1Z3 ("Cardiome"), MERCK SHARP & DOHME (SWITZERLAND) GMBH, a company organized under the laws of Switzerland with offices at Rue de Lausanne 27, Sion, 1950, Switzerland (“MSD Switzerland”) and MERCK SHARP & DOHME CORP. (as successor-in-interest to the entity formerly known as Merck & Co., Inc.), a corporation organized under the laws of New Jersey with offices at One Merck Drive, Whitehouse Station, NJ 08889-0100, U.S.A. (“MSD Corp.” and, together with MSD Switzerland, “Merck”). Cardiome, MSD Switzerland and MSD Corp. are each referred to from time to time herein either individually as a “Party” or collectively as the “Parties”.
TRANSITION AGREEMENTTransition Agreement • May 6th, 2013 • Cardiome Pharma Corp • Pharmaceutical preparations
Contract Type FiledMay 6th, 2013 Company IndustryThis Transition Agreement (the “Agreement”) is made and entered into as of the latest date of signature appearing below (the “Effective Date”) by and between CARDIOME PHARMA CORP., a Canadian corporation with offices at 6190 Agronomy Rd., Suite 405, Vancouver, B.C., Canada, V6T 1Z3 ("Cardiome"), and MERCK SHARP & DOHME CORP. (as successor-in-interest to the entity formerly known as Merck & Co., Inc.), a corporation organized under the laws of New Jersey with offices at One Merck Drive, Whitehouse Station, NJ 08889-0100, U.S.A. ("Merck"). Cardiome and Merck are each referred to from time to time herein either individually as a “Party” or collectively as the “Parties”.